Filing Analysis
Fulcrum Therapeutics announced the departure of Greg Tourangeau, Vice President, Finance and Principal Accounting Officer, effective August 7, 2026. The company has appointed CFO Alan Musso to serve as the interim Principal Accounting Officer.
🚩 Red Flags
- Departure of a key financial officer (Principal Accounting Officer) can sometimes signal internal control or reporting issues, though not explicitly stated here.
- Succession is an internal reassignment rather than the hiring of a dedicated new hire, indicating potential resource constraints or rapid turnover.
📋 Key Facts
- Greg Tourangeau departed from his roles as VP, Finance and Principal Accounting Officer on August 7, 2026.
- Departure was by mutual agreement following a previous disclosure on June 11, 2026.
- Alan Musso (CFO) appointed as Principal Accounting Officer effective August 7, 2026.
- Mr. Musso will receive no additional compensation for this appointment.
Fulcrum Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders held on June 24, 2026. The meeting included elections for Class I directors and advisory votes on executive compensation and auditor ratification.
📋 Key Facts
- Stockholders elected Sonja Banks, Alan Ezekowitz, and Colin Hill as Class I directors for three-year terms ending in 2029.
- Non-binding advisory vote to approve executive officer compensation was approved with 50,735,617 votes 'For'.
- Stockholders ratified the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026.
Fulcrum Therapeutics announced a significant underwritten public offering of common stock and pre-funded warrants to raise approximately $164.1 million in net proceeds. The offering includes 11,853,960 total shares (including option shares) at a price of $13.50 per share.
🚩 Red Flags
- Significant dilution to existing shareholders through the issuance of over 11 million new shares and warrants.
- Use of pre-funded warrants can be a mechanism to bypass certain ownership thresholds while still providing equity-like exposure.
📋 Key Facts
- Underwritten public offering of 11,851,853 shares of common stock at $13.50 per share.
- Issuance of pre-funded warrants to purchase up to 1,111,193 shares at a price of $13.499 per warrant.
- Underwriters have a 30-day option to purchase an additional 1,944,456 shares (Option Shares).
- Estimated net proceeds: ~$164.1 million ($188.1 million if option is fully exercised).
- Pre-funded warrants are exercisable at any time with a $0.001 exercise price.
- Lock-up period: 60 days for the company and 30 days for directors/executive officers regarding selling shares.
Fulcrum Therapeutics announced positive initial clinical results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir in treating sickle cell disease (SCD). The data showed significant increases in fetal hemoglobin (HbF) and improved markers of hemolysis, alongside a favorable safety profile.
🚩 Red Flags
- Clinical trial results are based on a limited sample size (n=12 for the 20 mg cohort) and early timepoints, which may not be predictive of long-term or full cohort outcomes.
- Forward-looking statements highlight risks regarding capital needs to achieve business objectives.
📋 Key Facts
- Mean absolute HbF increased by 9.9% at 6 weeks in the 20 mg cohort (vs. 5.6% in the 12 mg cohort).
- 58% of patients in the 20 mg cohort achieved absolute HbF levels ≥20% at Week 6.
- Observed dose-response: >3.75-fold mean induction of HbF at Week 12 for the 20 mg group vs. 2.4-fold in the 12 mg group.
- 67% of patients (8 of 12) reported no vaso-occlusive crises (VOCs) during the treatment period as of Nov 11, 2025.
- Safety profile remained consistent with previous data; no treatment-related serious adverse events or discontinuations reported in this cohort.
- Company plans to submit an IND application for bone marrow failure syndromes in Q2 2026.
Fulcrum Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal mechanism to furnish quarterly earnings data via a press release.
📋 Key Facts
- Report date: October 29, 2025
- Reporting period: Quarter ended September 30, 2025
- The company furnished Exhibit 99.1 containing the full text of the press release regarding financial results.
- The information under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Fulcrum Therapeutics, Inc. has filed an 8-K to furnish an updated corporate presentation under Regulation FD. The filing is intended for use in investor meetings and conferences.
📋 Key Facts
- The company released an updated corporate presentation on August 28, 2025.
- The presentation is furnished as Exhibit 99.1.
- Information provided under Item 7.01 is considered 'furnished' rather than 'filed', meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Fulcrum Therapeutics announced its Q2 2025 financial results and provided positive clinical data from the 12 mg dose cohort of its Phase 1b trial for pociredir in treating sickle cell disease (SCD). The clinical update showed significant increases in fetal hemoglobin (HbF) and improved markers of hemolysis with a favorable safety profile.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Announced financial results for the quarter ended June 30, 2025.
- Phase 1b trial (12 mg dose cohort, n=16) showed mean HbF increased from 7.6% to 16.2% at 12 weeks.
- Seven of 16 patients achieved absolute HbF levels > 20%, a threshold associated with ~90% reduction in vaso-occlusive crises (VOCs).
- Mean hemoglobin concentration increased from 7.8 g/dL to 8.7 g/dL at 12 weeks.
- Safety profile: No drug-related serious adverse events and no discontinuations due to treatment-emergent adverse events in the 12 mg cohort.
- 50% of patients (8 of 16) reported zero VOCs during the 12-week treatment period.
Fulcrum Therapeutics reported the results of its 2025 annual meeting of stockholders held on June 26, 2025. The meeting included elections for three class III directors and advisory votes regarding executive compensation frequency and auditor ratification.
📋 Key Facts
- Elected Katina Dorton, Robert Gould, and Kate Haviland as Class III directors for three-year terms ending in 2028.
- Stockholders approved the non-binding advisory vote on executive officer compensation (Say-on-Pay).
- Stockholders selected 'one year' as the recommended frequency for future non-binding advisory votes on executive compensation.
- Ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Fulcrum Therapeutics announced its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal notice of the earnings release issued via press release.
📋 Key Facts
- Report date: May 1, 2025
- Reporting period: Quarter ended March 31, 2025
- The company furnished Exhibit 99.1 containing the full text of the earnings press release.
- CEO Alex C. Sapir signed the report.
Fulcrum Therapeutics announced that MyoKardia, Inc. (a Bristol-Myers Squibb subsidiary) has elected to terminate its collaboration and license agreement for the development of cardiomyopathy gene targets. The termination will be effective June 26, 2025.
🚩 Red Flags
- Loss of significant potential revenue stream: The termination eliminates access to hundreds of millions in aggregate milestone payments and tiered royalties.
- Termination for convenience: MyoKardia exercised its right to exit the deal without needing to prove a breach, suggesting a strategic shift or loss of interest in Fulcrum's specific targets.
📋 Key Facts
- Termination notice received on February 26, 2025; effective date is June 26, 2025 (120-day notice period).
- The agreement allowed for potential milestone payments of up to $298.5 million per target and $150.0 million per target for other targets.
- Fulcrum had already achieved a $2.5 million preclinical milestone.
- Upon termination, Fulcrum will lose all rights to future milestones, royalties (mid-single to low-double digit %), and research cost reimbursements.
- MyoKardia is a wholly-owned subsidiary of Bristol-Myers Squibb Company.
Fulcrum Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: February 25, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Fulcrum Therapeutics issued an 8-K to provide a preliminary update on its financial position as of December 31, 2024. The company expects to report approximately $240 million in cash, cash equivalents, and marketable securities.
🚩 Red Flags
- Information is unaudited and subject to change upon completion of the annual audit.
📋 Key Facts
- Expected cash, cash equivalents, and marketable securities: ~$240 million as of Dec 31, 2024.
- The financial information provided is unaudited and preliminary.
- Full audit for the fiscal year ended December 31, 2024, is currently ongoing.
Fulcrum Therapeutics announced that Sanofi (via Genzyme Corporation) has exercised its right to terminate their collaboration and license agreement for losmapimod outside the U.S. for convenience. The termination is set to become effective on April 17, 2025.
🚩 Red Flags
- Loss of significant future revenue streams including royalties and up to $975M in potential milestones.
- Termination 'for convenience' by a major partner (Sanofi) often signals a shift in strategic priority or lack of confidence in the asset's commercial path outside the U.S.
- Significant reduction in projected cash inflows from global development cost reimbursements.
📋 Key Facts
- Sanofi elected to terminate the May 11, 2024, collaboration and license agreement for 'convenience'.
- Termination effective date: April 17, 2025 (120 days from notice).
- Fulcrum will lose all rights to future milestone payments, royalties, and global development cost reimbursements upon termination.
- The original deal included an $80.0 million upfront payment and up to $975.0 million in potential milestones/royalties (low-teens to mid-twenties range).
- Fulcrum retains manufacturing rights for U.S. commercialization and its own activities under the global development plan.
Fulcrum Therapeutics announced its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a formal notice that quarterly earnings data has been released via an attached press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is classified as an emerging growth company.
Fulcrum Therapeutics announced the resignation of Class II director James J. Collins, effective November 12, 2024. The company simultaneously appointed Rachel King to fill the vacancy and transitioned Dr. Collins into a consulting role.
🚩 Red Flags
- None identified; departure was amicable and includes a transition to a consulting role.
📋 Key Facts
- James J. Collins resigned from the Board and all committees effective Nov 12, 2024.
- Dr. Collins' resignation was not due to any disagreement with the company regarding operations, policies, or practices.
- Fulcrum will engage Dr. Collins as a consultant to advise on science and technology matters.
- Rachel King appointed to Board (Class II) effective Nov 12, 2024; term expires at 2027 annual meeting.
- Ms. King is deemed 'independent' by Nasdaq standards and will serve on the Compensation & Human Capital Management Committee.
- Ms. King received a one-time nonqualified stock option for 60,000 shares with an exercise price of $3.64 per share.
Fulcrum Therapeutics announced a strategic reprioritization of its R&D activities, resulting in a significant workforce reduction from 80 to 51 full-time employees. The company aims to focus resources on pociredir (sickle cell disease) and Diamond-Blackfan anemia programs while cutting annual operating expenses by approximately $10 million.
🚩 Red Flags
- Significant workforce reduction (36% decrease in headcount) often indicates liquidity constraints or a pivot due to clinical/financial pressure.
- Forward-looking statements explicitly mention the risk of 'raising the substantial additional capital needed to achieve its business objectives,' signaling potential future dilution.
📋 Key Facts
- Workforce reduction from 80 to 51 full-time employees announced on September 24, 2024.
- One-time costs of approximately $2.0 million expected for severance payments in Q3 2024.
- Expected annual operating expense savings of ~$10.0 million starting in Q1 2025.
- Strategic shift to focus on pociredir (sickle cell disease), Diamond-Blackfan anemia, and early discovery programs.
- Suspension of losmapimod development mentioned in forward-looking statements.
Fulcrum Therapeutics announced that its Phase 3 REACH clinical trial for losmapimod in treating FSHD failed to meet its primary endpoint. The drug also failed to achieve nominal statistical significance across secondary endpoints, though the safety profile remained consistent with previous studies.
🚩 Red Flags
- Failure of a Phase 3 clinical trial for the lead candidate (losmapimod) is a major setback for a biotech company's pipeline value.
- Lack of statistical significance in secondary endpoints reduces the likelihood of regulatory approval or commercial viability for this indication.
📋 Key Facts
- Phase 3 REACH clinical trial results were released on September 12, 2024.
- The trial failed to meet its primary endpoint (change from baseline in relative surface area) compared to placebo.
- Secondary endpoints did not achieve nominal statistical significance.
- Safety and tolerability profile of losmapimod was consistent with previously reported studies.
Fulcrum Therapeutics entered into exchange agreements with RA Capital Healthcare Fund, L.P. and another institutional stockholder to convert common stock into pre-funded warrants. This transaction involves a total of 9,350,000 shares being converted into warrants.
🚩 Red Flags
- Conversion of common stock into pre-funded warrants can be seen as a way to delay the impact of dilution on existing shareholders, though it effectively locks in the conversion at current levels.
- The use of 'beneficial ownership blockers' is common in micro/small-cap financing but indicates highly structured equity arrangements often used by institutional investors to manage regulatory thresholds.
📋 Key Facts
- Date of event: August 21, 2024.
- RA Capital Healthcare Fund, L.P. exchanged 8,500,000 shares for pre-funded warrants to acquire 8,500,000 shares.
- An unnamed institutional stockholder exchanged 850,000 shares for pre-funded warrants to acquire 850,000 shares.
- Warrants have an exercise price of $0.001 per share and are immediately exercisable with no expiration date.
- The warrants include a beneficial ownership blocker (9.99% threshold) designed to prevent holders from exceeding certain ownership limits upon exercise.
Fulcrum Therapeutics announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Report date: July 31, 2024
- Reporting period: Quarter ended June 30, 2024
- The company is an emerging growth company.
- Financial results were furnished via Exhibit 99.1 (Press Release).
Fulcrum Therapeutics announced the election of Colin Hill to its Board of Directors and provided results from its 2024 annual meeting of stockholders. The filing also notes the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Colin Hill was elected to the Board on June 17, 2024, increasing the Board size from eight to nine members.
- Mr. Hill will serve as a Class I director and join the Science & Technology Committee.
- Mr. Hill received a one-time nonqualified stock option for 60,000 shares at an exercise price of $7.00 per share.
- Stockholders elected James Collins, James Geraghty, and Alex Sapir as Class II directors for three-year terms ending in 2027.
- Stockholders ratified the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024.
Fulcrum Therapeutics entered into a significant collaboration and license agreement with Sanofi (via Genzyme Corporation) for the international commercialization of losmapimod. The deal includes an $80 million upfront payment and substantial milestone/royalty potential.
🚩 Red Flags
- Restrictive covenant: Fulcrum is prohibited from researching/developing any p38a/b MAPK modulator anywhere in the world, except losmapimod in the U.S.
- Sanofi retains the right to terminate the agreement for convenience on a product-by-product or region-by-region basis.
📋 Key Facts
- Sanofi granted exclusive license to commercialize losmapimod outside the U.S.
- Fulcrum receives $80.0 million upfront payment from Sanofi.
- Fulcrum is eligible for up to $975.0 million in regulatory and sales-based milestones.
- Tiered royalties ranging from low-teens to mid-twenties on non-U.S. net sales.
- Fulcrum and Sanofi will equally share global development costs for the Phase 3 clinical trial.
- Fulcrum retains sole manufacturing rights for U.S. activities and initial supply to Sanofi.
Fulcrum Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a formal mechanism to furnish quarterly earnings data via press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Filing date: February 27, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is classified as an emerging growth company.